A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome
Introduction: Differentiation between sepsis and systemic inflammatory response syndrome (SIRS) remains a diagnostic challenge to physicians because they may have a similar clinical presentation. A rapid and accurate diagnostic tool that can distinguish between these two conditions will help in the proper therapeutic decision making. This prospective study was performed to evaluate the diagnostic and prognostic utility soluble urokinase-type plasminogen activator receptor (Supar) and procalcitonin (PCT) in patients with sepsis and SIRS.
Materials and Methods: Eighty-eight patients were enrolled, of which 29 are SIRS and sepsis 59 is a patient. Supar and PCT level was measured on the day of admission (day 1), day 3 and day 7.
Results: Levels Supar and PCT was significantly higher (p = 0.05 and p <0.001, respectively) in the sepsis group compared with SIRS group. Soluble urokinase-type plasminogen activator receptor is a better diagnostic tool in predicting sepsis more PCT [area under the curve (AUC) was 0.89 vs. 0.82] on day 1. The best cutoff for Supar was 5.58 pg / mL [ 96% sensitivity and 90% negative predictive value (NPV)] and the best cut-off for PCT was 1.96 ng / mL (sensitivity 93.1% and 80% NPV). However, the PCT has a better prognostic trend (p = 0.006) to identify nonsurvivors in sepsis group.
Conclusions: Our findings suggest that both Supar and PCT can be used as a potential test for distinguishing between SIRS and sepsis. Procalcitonin showed a significant prognostic trends to identify nonsurvivors. Soluble urokinase-type plasminogen activator receptor showed better diagnostic potential of PCT on day 1.
Clinical significance: Second Supar and PCT can be used as a surrogate biomarker to distinguish sepsis from SIRS. Procalcitonin showed a significant prognostic trends to identify nonsurvivors can help physicians to take clinical decisions that are relevant. Also, the use of biomarkers such as PCT and Supar can reduce the use of antibiotics in SIRS noninfective.
How to cite this article: Sharma A, Ray S, Mamidipalli R, Kakar A, Chugh P, Jain R, et al. A Comparative Study of the Diagnostic and Utility late prognosis Urokinase-type Plasminogen Activator Receptor and procalcitonin in patients with Sepsis and Systemic Inflammatory Response Syndrome.
A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome
Late Urokinase Plasminogen Activator Receptor (Supar) concentrations were elevated in patients with Neuroendocrine Malignancies
Neuroendocrine neoplasia (NEN) comprise a heterogeneous tumors that are challenging to diagnose and, especially in cases of poorly differentiated (G3) Nen, is associated with a very limited survival. Novel biomarkers enabling early diagnosis and optimal selection of appropriate treatment options are needed to improve patient outcomes. More recently, changes in serum levels of soluble urokinase-type plasminogen activator receptor (Supar) is described in various types of cancer. However, Supar outstanding role as a biomarker in patients with unknown Nen.
In this study, we measured serum levels in a cohort Supar large and well-marked from 187 patients with NEN (neuroendocrine carcinoma (NEC) n = 30; neuroendocrine tumors (NET), n = 157) and 44 healthy controls. Supar concentration was significantly increased in patients compared with controls. crine carcinoma (NEC) n = 30; neuroendocrine tumors (NET), n = 157) and 44 healthy controls.
Supar concentration was significantly increased in patients compared with controls. However, the concentration of Supar independent of tumor-related factors such as proliferation activity by Ki-67, tumor grading, TNM (TNM classification of malignant tumor) stage, the expression of somatostatin receptors or clinical features such as functional or nonfunctional disease and the presence of tumor recurrence.
Description: Quantitativesandwich ELISA kit for measuring Human Phosphoglucomutase-1 (PGM1) in samples from serum, plasma, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Human Phosphoglucomutase-1(PGM1) in samples from serum, plasma, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitative sandwich ELISA for measuring Human Phosphoglucomutase-1 (PGM1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Phosphoglucomutase-1 (PGM1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Phosphoglucomutase-1 (PGM1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: A polyclonal antibody against PGM1. Recognizes PGM1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF
Description: A polyclonal antibody against PGM1. Recognizes PGM1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200, IF:1:50-1:200
Description: A polyclonal antibody against PGM2. Recognizes PGM2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC
Antibodies | Assay Kits | Biology Cells | cDNA | Culture Cells | Devices | DNA | DNA Testing | Elisa Kits | Enzymes | Exosomes | Gels | Isotypes | Medium & Serums | Particles | PCR | Pcr Kits | Peptides | Recombinant Proteins | Ria Kits | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Elisa Kits | Equipments | Gels | Isotypes | Medium & Serums | NATtrol | Particles | PCR | Pcr Kits | Peptides | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Enzymes | Equipments | Exosomes | Isotypes | Medium & Serums | NATtrol | Particles | PCR | Pcr Kits | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Devices | DNA | DNA Testing | Elisa Kits | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | Panel | Particles | PCR | Pcr Kits | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot
No Comment